Low risk of nevirapine resistance mutations in the prevention of mother-to-child transmission of HIV-1: Agence Nationale de Recherches sur le SIDA Ditrame Plus, Abidjan, Cote d'Ivoire

被引：54

作者：

Chaix, ML ^{[1
]}

Ekouevi, DK ^{[1
]}

Rouet, F ^{[1
]}

Tonwe-Gold, B ^{[1
]}

Viho, I ^{[1
]}

Bequet, L ^{[1
]}

Peytavin, G ^{[1
]}

Toure, H ^{[1
]}

Menan, H ^{[1
]}

Leroy, V ^{[1
]}

Dabis, F ^{[1
]}

Rouzioux, C ^{[1
]}

机构：

[1] Univ Victor Segalen, INSERM U593, ISPED, F-33076 Bordeaux, France

来源：

JOURNAL OF INFECTIOUS DISEASES | 2006年 / 193卷 / 04期

关键词：

D O I：

10.1086/499966

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

The frequency of resistance mutations was estimated in the cohort of Agence Nationale de Recherches sur le SIDA Ditrame Plus, a study that evaluated the combination of short-course zidovudine ( ZDV) plus lamivudine ( 3TC) and single-dose nevirapine ( SD-NVP) followed by 3 days of postpartum ZDV plus 3TC for the prevention of mother-to-child transmission of human immunodeficiency virus type 1 ( HIV-1). The frequency with which resistance mutations were detected in mothers at week 4 postpartum was 1.14% ( 95% confidence interval [ CI], 0.03% - 6.17%) for NVP and 8.33% ( 95% CI, 3.66% - 15.76%) for 3TC. In multivariate analysis, 3TC resistance was associated with a longer duration of ZDV plus 3TC prepartum prophylaxis (P = .009). This regimen, which is feasible in resource-limited settings, prevents most peripartum HIV-1 transmission and minimizes the development of NVP resistance.

引用

页码：482 / 487

页数：6

共 15 条

[1] [Anonymous], 2004, ANT DRUGS TREAT PREG
[2] CHAIX ML, 2004, ANTIVIR THER, V9, pS176
[3] Development of resistance mutations in women receiving standard antiretroviral therapy who received intrapartum nevirapine to prevent perinatal human immunodeficiency virus type 1 transmission: A substudy of Pediatric AIDS Clinical Trials Group protocol 316
Cunningham, CK
Chaix, ML
Rekacewicz, C
Britto, P
Rouzioux, C
Gelber, RD
Dorenbaum, A
Delfraissy, JF
Bazin, B
Mofenson, L
Sullivan, JL
[J]. JOURNAL OF INFECTIOUS DISEASES, 2002, 186 (02) : 181 - 188
[4] Dabis F, 2005, AIDS, V19, P309
[5] Nevirapine (NVP) resistance in women with HIV-1 subtype C, compared with subtypes A and D, after the administration of single-dose NVP
Eshleman, SH
Hoover, DR
Chen, S
Hudelson, SE
Guay, LA
Mwatha, A
Fiscus, SA
Mmiro, F
Musoke, P
Jackson, JB
Kumwenda, N
Taha, T
[J]. JOURNAL OF INFECTIOUS DISEASES, 2005, 192 (01) : 30 - 36
[6] Selection and fading of resistance mutations in women and infants receiving nevirapine to prevent HIV-1 vertical transmission (HIVNET 012)
Eshleman, SH
Mracna, M
Guay, LA
Deseyve, M
Cunningham, S
Mirochnick, M
Musoke, P
Fleming, T
Fowler, MG
Mofenson, LM
Mmiro, F
Jackson, JB
[J]. AIDS, 2001, 15 (15) : 1951 - 1957
[7] FELSENSTEIN J, 2001, PHYLIP VERSION 3 6 X
[8] Emergence of drug-resistant HIV-1 after intrapartum administration of single-dose nevirapine is substantially underestimated
Johnson, JA
Li, JF
Morris, L
Martinson, N
Gray, G
McIntyre, J
Heneine, W
[J]. JOURNAL OF INFECTIOUS DISEASES, 2005, 192 (01) : 16 - 23
[9] Intrapartum exposure to nevirapine and subsequent maternal responses to nevirapine-based antiretroviral therapy
Jourdain, G
Ngo-Giang-Huong, N
Le Coeur, S
Bowonwatanuwong, C
Kantipong, P
Leechanachai, P
Ariyadej, S
Leenasirimakul, P
Hammer, S
Lallemant, M
[J]. NEW ENGLAND JOURNAL OF MEDICINE, 2004, 351 (03) : 229 - 240
[10] Single-dose perinatal nevirapine plus standard zidovudine to prevent mother-to-child transmission of HIV-1 in Thailand
Lallemant, M
Jourdain, G
Le Coeur, S
Mary, JY
Ngo-Giang-Huong, N
Koetsawang, S
Kanshana, S
McIntosh, K
Thaineua, V
[J]. NEW ENGLAND JOURNAL OF MEDICINE, 2004, 351 (03) : 217 - 228

← 1 2 →